芽球形質細胞様樹状細胞腫瘍の市場規模、シェア、動向分析レポート：治療別、最終用途別、セグメント別予測、2024年～2030年

芽球形質細胞様樹状細胞腫瘍市場の成長と動向：

Grand View Research社の最新レポートによると、芽球形質細胞様樹状細胞腫瘍の世界市場規模は2030年までに2億1,427万米ドルに達すると予測され、2024年から2030年までのCAGRは7.7％で成長すると予測されています。

この市場には、この稀な血液悪性腫瘍の診断、治療、管理に不可欠な様々な要素が含まれています。

BPDCNの罹患率は、診断方法の向上とヘルスケアプロバイダーや患者の意識の高まりにより、増加傾向にあります。この罹患率の増加は、効果的な治療に対する需要を押し上げます。BPDCNの分子的・遺伝的側面の理解における著しい進歩は、標的療法の開発につながり、有望な薬剤が臨床試験中です。

BPDCNは様々な地域で希少疾病に分類されており、市場独占権の延長や税額控除などの優遇措置により、医薬品への投資を促しています。個別化医療へのシフトにより、遺伝子プロファイルに基づく治療戦略が強化され、オーダーメイド治療市場が拡大しています。

芽球形質細胞様樹状細胞腫瘍市場レポート・ハイライト

• 治療別では、化学療法が2023年に38.7%の最大売上シェアで市場を独占。化学療法とtagraxofuspのような新規薬剤の併用はBPDCN治療を一変させる。このことは、化学療法の極めて重要な役割を浮き彫りにし、治療成績の改善と標的療法のイントロダクションを通じて市場成長を促進します。
• 最終用途に基づくと、病院が2023年に57.5%の最大収益シェアで市場を独占しました。米国と欧州で年間1,000～1,400例と推定されるBPDCNの罹患率の上昇により、病院への受診が増加しました。先進的な診断ツールと腫瘍科の専門化により、効果的な治療開始に不可欠なタイムリーで正確な診断が容易になった。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 芽球形質細胞様樹状細胞腫瘍市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 芽球形質細胞様樹状細胞腫瘍市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 芽球形質細胞様樹状細胞腫瘍市場：治療別推定・動向分析

• 世界の芽球形質細胞様樹状細胞腫瘍市場：治療ダ別ッシュボード
• 世界の芽球形質細胞様樹状細胞腫瘍市場：治療別変動分析
• 治療別収益
• 化学療法
• 免疫療法
• 幹細胞移植
• 標的療法
• その他

第5章 芽球形質細胞様樹状細胞腫瘍市場： 最終用途別推定・動向分析

• 世界の芽球形質細胞様樹状細胞腫瘍市場：最終用途別ダッシュボード
• 世界の芽球形質細胞様樹状細胞腫瘍市場：最終用途別変動分析
• 最終用途別収益
• 病院
• 専門クリニック
• その他

第6章 芽球形質細胞様樹状細胞腫瘍市場：治療および最終用途別の地域別推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • 主要企業の市場シェア分析、2023年
  • AbbVie Inc.
  • ImmunoGen, Inc.
  • Mustang Bio
  • Genentech, Inc.
  • Stemline Therapeutics, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Cellex Patient Treatment GmbH
  • Xencor
  • Resverlogix

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Blastic plasmacytoid dendritic cell neoplasm market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 4 North America Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 5 U.S. Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 6 U.S. Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 7 Canada Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 8 Canada Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 9 Mexico Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 10 Mexico Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 11 Europe Blastic plasmacytoid dendritic cell neoplasm market, by region, 2018 - 2030 (USD Million)
• Table 12 Europe Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 13 Europe Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 14 Germany Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 15 Germany Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 16 UK Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 17 UK Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 18 France Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 19 France Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 20 Italy Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 21 Italy Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 22 Spain Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 23 Spain Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 24 Denmark Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 25 Denmark Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 26 Sweden Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 27 Sweden Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 28 Norway Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 29 Norway Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific Blastic plasmacytoid dendritic cell neoplasm market, by region, 2018 - 2030 (USD Million)
• Table 31 Asia Pacific Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 32 Asia Pacific Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 33 China Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 34 China Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 35 Japan Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 36 Japan Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 37 India Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 38 India Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 39 South Korea Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 40 South Korea Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 41 Australia Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 42 Australia Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 43 Thailand Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 44 Thailand Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 45 Latin America Blastic plasmacytoid dendritic cell neoplasm market, by region, 2018 - 2030 (USD Million)
• Table 46 Latin America Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 47 Latin America Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 48 Brazil Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 49 Brazil Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 50 Argentina Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 51 Argentina Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 52 MEA Blastic plasmacytoid dendritic cell neoplasm market, by region, 2018 - 2030 (USD Million)
• Table 53 MEA Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 54 MEA Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 55 South Africa Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 56 South Africa Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 57 Saudi Arabia Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 58 Saudi Arabia Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 59 UAE Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 60 UAE Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)
• Table 61 Kuwait Blastic plasmacytoid dendritic cell neoplasm market, by treatment, 2018 - 2030 (USD Million)
• Table 62 Kuwait Blastic plasmacytoid dendritic cell neoplasm market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Market research approaches
• Fig. 4 QFD modeling for market share assessment
• Fig. 5 Market formulation & validation
• Fig. 6 Blastic plasmacytoid dendritic cell neoplasm market: market outlook
• Fig. 7 Blastic plasmacytoid dendritic cell neoplasm competitive insights
• Fig. 8 Parent market outlook
• Fig. 9 Related/ancillary market outlook
• Fig. 10 Blastic plasmacytoid dendritic cell neoplasm market driver impact
• Fig. 11 Blastic plasmacytoid dendritic cell neoplasm market restraint impact
• Fig. 12 Blastic plasmacytoid dendritic cell neoplasm market: Treatment movement analysis
• Fig. 13 Blastic plasmacytoid dendritic cell neoplasm market: Treatment outlook and key takeaways
• Fig. 14 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 15 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 16 Stem cell transplantation market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 17 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Blastic plasmacytoid dendritic cell neoplasm market: End Use movement analysis
• Fig. 20 Blastic plasmacytoid dendritic cell neoplasm market: End Use outlook and key takeaways
• Fig. 21 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Specialty Clinics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Global blastic plasmacytoid dendritic cell neoplasm market: Regional movement analysis
• Fig. 25 Global blastic plasmacytoid dendritic cell neoplasm market: Regional outlook and key takeaways
• Fig. 26 Global blastic plasmacytoid dendritic cell neoplasm market share and leading players
• Fig. 27 North America, by country
• Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 U.S. key country dynamics
• Fig. 30 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Canada key country dynamics
• Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Mexico key country dynamics
• Fig. 34 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 UK key country dynamics
• Fig. 37 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Germany key country dynamics
• Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 France key country dynamics
• Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Italy key country dynamics
• Fig. 43 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Spain key country dynamics
• Fig. 45 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Denmark key country dynamics
• Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Sweden key country dynamics
• Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Norway key country dynamics
• Fig. 51 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 China key country dynamics
• Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Japan key country dynamics
• Fig. 56 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 India key country dynamics
• Fig. 58 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Thailand key country dynamics
• Fig. 60 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 South Korea key country dynamics
• Fig. 62 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Australia key country dynamics
• Fig. 64 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Brazil key country dynamics
• Fig. 67 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Argentina key country dynamics
• Fig. 69 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 South Africa key country dynamics
• Fig. 72 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Saudi Arabia key country dynamics
• Fig. 74 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 UAE key country dynamics
• Fig. 76 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Kuwait key country dynamics
• Fig. 78 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Market share of key market players - Blastic Plasmacytoid Dendritic Cell Neoplasm market

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Growth & Trends:

The global blastic plasmacytoid dendritic cell neoplasm market size is anticipated to reach USD 214.27 million by 2030 and is projected to grow at a CAGR of 7.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a range of elements critical to diagnosing, treating, and managing this rare hematological malignancy.

The incidence of BPDCN is increasing, attributed to better diagnostic methods and heightened awareness among healthcare providers and patients. This rise in incidence boosts the demand for effective treatments. Significant advancements in understanding BPDCN's molecular and genetic aspects led to the development of targeted therapies, with promising drugs undergoing clinical trials.

BPDCN is classified as an orphan disease in various regions, encouraging pharmaceutical investment through incentives such as extended market exclusivity and tax credits. The shift towards personalized medicine enhances treatment strategies based on genetic profiles, expanding the market for customized therapies.

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Report Highlights:

• Based on treatment, Chemotherapy dominated the market with the largest revenue share of 38.7% in 2023. Combining chemotherapy with novel agents such as tagraxofusp transforms BPDCN treatment. This highlights chemotherapy's pivotal role and drives market growth through improved outcomes and the introduction of targeted therapies.
• Based on end use, hospitals dominated the market with the largest revenue share of 57.5% in 2023. The rising incidence of BPDCN, estimated at 1,000 to 1,400 cases annually in the U.S. and Europe, increased hospital visits. Advanced diagnostic tools and specialized oncology departments facilitate timely and accurate diagnoses essential for effective treatment initiation.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing incidence rates of BPDCN
    • 3.2.1.2. Advancements in treatment options
    • 3.2.1.3. Growing awareness and diagnosis of rare hematological malignancies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited treatment option
    • 3.2.2.2. Challenges in diagnosis
• 3.3. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Treatment Estimates & Trend Analysis

• 4.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Treatment Dashboard
• 4.2. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Treatment Movement Analysis
• 4.3. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market by Treatment, Revenue
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Immunotherapy
  • 4.5.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Stem Cell Transplantation
  • 4.6.1. Stem cell transplantation market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Targeted Therapy
  • 4.7.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Other
  • 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Blastic Plasmacytoid Dendritic Cell Neoplasm Market: End Use Estimates & Trend Analysis

• 5.1. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: End Use Dashboard
• 5.2. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market: End Use Movement Analysis
• 5.3. Global Blastic Plasmacytoid Dendritic Cell Neoplasm Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Blastic Plasmacytoid Dendritic Cell Neoplasm Market: Regional Estimates & Trend Analysis by Treatments, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key company market share analysis, 2023
  • 7.2.3. AbbVie Inc.
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. ImmunoGen, Inc.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Mustang Bio
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Genentech, Inc.
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Stemline Therapeutics, Inc.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Jazz Pharmaceuticals, Inc.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Cellex Patient Treatment GmbH
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Xencor
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Resverlogix
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives